{"id":7502,"date":"2023-09-25T11:42:55","date_gmt":"2023-09-25T08:12:55","guid":{"rendered":"https:\/\/cedalco.com\/?post_type=dt_portfolio&#038;p=7502"},"modified":"2026-01-09T21:45:46","modified_gmt":"2026-01-09T18:15:46","slug":"etopodal","status":"publish","type":"dt_portfolio","link":"https:\/\/cedalco.com\/en\/project\/etopodal\/","title":{"rendered":"Etopodal"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-post\" data-elementor-id=\"7502\" class=\"elementor elementor-7502 elementor-7315\" data-elementor-post-type=\"dt_portfolio\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-ec83bae elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"ec83bae\" data-element_type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-71d7078\" data-id=\"71d7078\" data-element_type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-inner-section elementor-element elementor-element-5bd56d8 elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"5bd56d8\" data-element_type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-50 elementor-inner-column elementor-element elementor-element-cfb69bc\" data-id=\"cfb69bc\" data-element_type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-c40384a elementor-widget elementor-widget-image\" data-id=\"c40384a\" data-element_type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t<figure class=\"wp-caption\">\n\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/cedalco.com\/wp-content\/uploads\/2023\/09\/Etopodal100.jpeg\" data-elementor-open-lightbox=\"yes\" data-elementor-lightbox-title=\"Etopodal100\" data-e-action-hash=\"#elementor-action%3Aaction%3Dlightbox%26settings%3DeyJpZCI6ODAzOCwidXJsIjoiaHR0cHM6XC9cL2NlZGFsY28uY29tXC93cC1jb250ZW50XC91cGxvYWRzXC8yMDIzXC8wOVwvRXRvcG9kYWwxMDAuanBlZyJ9\">\n\t\t\t\t\t\t\t<img fetchpriority=\"high\" decoding=\"async\" width=\"858\" height=\"800\" src=\"https:\/\/cedalco.com\/wp-content\/uploads\/2023\/09\/Etopodal100.jpeg\" class=\"elementor-animation-float attachment-full size-full wp-image-8038\" alt=\"\" srcset=\"https:\/\/cedalco.com\/wp-content\/uploads\/2023\/09\/Etopodal100.jpeg 858w, https:\/\/cedalco.com\/wp-content\/uploads\/2023\/09\/Etopodal100-300x280.jpeg 300w, https:\/\/cedalco.com\/wp-content\/uploads\/2023\/09\/Etopodal100-768x716.jpeg 768w\" sizes=\"(max-width: 858px) 100vw, 858px\" title=\"\">\t\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<figcaption class=\"widget-image-caption wp-caption-text\">Click on the photo to enlarge <i class=\"fa fa-search-plus\" aria-hidden=\"true\"><\/i><\/figcaption>\n\t\t\t\t\t\t\t\t\t\t<\/figure>\n\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t<div class=\"elementor-column elementor-col-50 elementor-inner-column elementor-element elementor-element-1971562\" data-id=\"1971562\" data-element_type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-cbc1ac2 elementor-widget__width-auto elementor-widget-mobile__width-inherit elementor-widget elementor-widget-theme-post-title elementor-page-title elementor-widget-heading\" data-id=\"cbc1ac2\" data-element_type=\"widget\" data-widget_type=\"theme-post-title.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t<h1 class=\"elementor-heading-title elementor-size-default\">Etopodal<sup>\u00ae<\/sup><\/h1>\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-83d0a3f elementor-widget elementor-widget-spacer\" data-id=\"83d0a3f\" data-element_type=\"widget\" data-widget_type=\"spacer.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<div class=\"elementor-spacer\">\n\t\t\t<div class=\"elementor-spacer-inner\"><\/div>\n\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-64bf8ea content-align-mobile-left elementor-widget__width-initial elementor-widget-mobile__width-inherit icon-box-vertical-align-top icon-position-left icon-vertical-align-start elementor-widget elementor-widget-the7_icon_box_widget\" data-id=\"64bf8ea\" data-element_type=\"widget\" data-widget_type=\"the7_icon_box_widget.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\n\t\t<div class=\"the7-box-wrapper the7-elementor-widget the7_icon_box_widget-64bf8ea\">\t\t\t<div class=\"box-content-wrapper\">\n\t\t\t\t\t\t\t\t\t<a class=\"elementor-icon-div\" >\t\t\t\t\t\t<div class=\"elementor-icon\">\n\t\t\t\t\t\t\t<i aria-hidden=\"true\" class=\"fas fa-circle-notch\"><\/i>\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/a>\t\t\t\t\t\t\t\t<div class=\"box-content\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h4 class=\"box-heading\">\n\t\t\t\t\t\t\t<a >\t\t\t\t\t\t\t\tGeneric Name\t\t\t\t\t\t\t<\/a>\t\t\t\t\t\t<\/h4>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<div class=\"box-description\">Etoposide <\/div>\n\t\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-3b23d5b content-align-mobile-left elementor-widget__width-initial elementor-widget-mobile__width-inherit icon-box-vertical-align-top icon-position-left icon-vertical-align-start elementor-widget elementor-widget-the7_icon_box_widget\" data-id=\"3b23d5b\" data-element_type=\"widget\" data-widget_type=\"the7_icon_box_widget.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\n\t\t<div class=\"the7-box-wrapper the7-elementor-widget the7_icon_box_widget-3b23d5b\">\t\t\t<div class=\"box-content-wrapper\">\n\t\t\t\t\t\t\t\t\t<a class=\"elementor-icon-div\" >\t\t\t\t\t\t<div class=\"elementor-icon\">\n\t\t\t\t\t\t\t<i aria-hidden=\"true\" class=\"fas fa-circle-notch\"><\/i>\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/a>\t\t\t\t\t\t\t\t<div class=\"box-content\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h4 class=\"box-heading\">\n\t\t\t\t\t\t\t<a >\t\t\t\t\t\t\t\tBrand Name\t\t\t\t\t\t\t<\/a>\t\t\t\t\t\t<\/h4>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<div class=\"box-description\"><sup>\u00ae<\/sup>Etopodal<\/div>\n\t\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-341ba6d elementor-widget__width-initial elementor-widget-mobile__width-inherit content-align-mobile-left icon-box-vertical-align-top icon-position-left icon-vertical-align-start elementor-widget elementor-widget-the7_icon_box_widget\" data-id=\"341ba6d\" data-element_type=\"widget\" data-widget_type=\"the7_icon_box_widget.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\n\t\t<div class=\"the7-box-wrapper the7-elementor-widget the7_icon_box_widget-341ba6d\">\t\t\t<div class=\"box-content-wrapper\">\n\t\t\t\t\t\t\t\t\t<a class=\"elementor-icon-div\" >\t\t\t\t\t\t<div class=\"elementor-icon\">\n\t\t\t\t\t\t\t<i aria-hidden=\"true\" class=\"fas fa-circle-notch\"><\/i>\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/a>\t\t\t\t\t\t\t\t<div class=\"box-content\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h4 class=\"box-heading\">\n\t\t\t\t\t\t\t<a >\t\t\t\t\t\t\t\tDrug Class\t\t\t\t\t\t\t<\/a>\t\t\t\t\t\t<\/h4>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<div class=\"box-description\">Antineoplastic Agent, Topoisomerase II Inhibitor<\/div>\n\t\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-6e17e6c elementor-widget__width-initial elementor-widget-mobile__width-inherit content-align-mobile-left icon-box-vertical-align-top icon-position-left icon-vertical-align-start elementor-widget elementor-widget-the7_icon_box_widget\" data-id=\"6e17e6c\" data-element_type=\"widget\" data-widget_type=\"the7_icon_box_widget.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\n\t\t<div class=\"the7-box-wrapper the7-elementor-widget the7_icon_box_widget-6e17e6c\">\t\t\t<div class=\"box-content-wrapper\">\n\t\t\t\t\t\t\t\t\t<a class=\"elementor-icon-div\" >\t\t\t\t\t\t<div class=\"elementor-icon\">\n\t\t\t\t\t\t\t<i aria-hidden=\"true\" class=\"fas fa-circle-notch\"><\/i>\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/a>\t\t\t\t\t\t\t\t<div class=\"box-content\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h4 class=\"box-heading\">\n\t\t\t\t\t\t\t<a >\t\t\t\t\t\t\t\tDosage Form\t\t\t\t\t\t\t<\/a>\t\t\t\t\t\t<\/h4>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<div class=\"box-description\">Solution for infusion 20mg\/ml (100 & 200ml)<\/div>\n\t\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<div class=\"elementor-element elementor-element-b26153d the7-e-tabs-view-vertical icon-align-left elementor-widget elementor-widget-the7-tabs\" data-id=\"b26153d\" data-element_type=\"widget\" data-settings=\"{&quot;accordion_breakpoint&quot;:&quot;mobile&quot;}\" data-widget_type=\"the7-tabs.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t<div class=\"the7-e-tabs-wrapper\">\n\t\t<div class=\"the7-e-tabs-nav-wrapper\">\n\t\t\t<div class=\"the7-e-tabs-nav-scroll-wrapper\">\n\t\t\t\t<div class=\"the7-e-tabs-nav\" role=\"tablist\">\n\t\t\t\t\t\t\t\t\t\t<span class=\"item-divider\" aria-hidden=\"true\"><\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t<div id=\"the7-e-tab-title-1871\" class=\"the7-e-tab-title\" aria-selected=\"true\" data-tab=\"1\" role=\"tab\" tabindex=\"0\" aria-controls=\"the7-e-tab-content-1871\" aria-expanded=\"false\">\n\t\t\t\t\t\t\t\t\t\t<span class=\"the7-e-tab-icon elementor-icon\" aria-hidden=\"true\"><i class=\"fas fa-virus\"><\/i><\/span>\n\t\t\t\t\t\t\t\t\t\t<h5 class=\"the7-e-tab-title-text\">\n\t\t\t\t\t\t\tIndications\t\t\t\t\t\t\t<\/h5>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<span class=\"item-divider\" aria-hidden=\"true\"><\/span>\n\t\t\t\t\t\t\t\t\t\t\t<div id=\"the7-e-tab-title-1872\" class=\"the7-e-tab-title\" aria-selected=\"false\" data-tab=\"2\" role=\"tab\" tabindex=\"-1\" aria-controls=\"the7-e-tab-content-1872\" aria-expanded=\"false\">\n\t\t\t\t\t\t\t\t\t\t<span class=\"the7-e-tab-icon elementor-icon\" aria-hidden=\"true\"><i class=\"fas fa-virus-slash\"><\/i><\/span>\n\t\t\t\t\t\t\t\t\t\t<h5 class=\"the7-e-tab-title-text\">\n\t\t\t\t\t\t\tContradications\t\t\t\t\t\t\t<\/h5>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<span class=\"item-divider\" aria-hidden=\"true\"><\/span>\n\t\t\t\t\t\t\t\t\t\t\t<div id=\"the7-e-tab-title-1873\" class=\"the7-e-tab-title\" aria-selected=\"false\" data-tab=\"3\" role=\"tab\" tabindex=\"-1\" aria-controls=\"the7-e-tab-content-1873\" aria-expanded=\"false\">\n\t\t\t\t\t\t\t\t\t\t<span class=\"the7-e-tab-icon elementor-icon\" aria-hidden=\"true\"><i class=\"fas fa-list-ul\"><\/i><\/span>\n\t\t\t\t\t\t\t\t\t\t<h5 class=\"the7-e-tab-title-text\">\n\t\t\t\t\t\t\tWarnings and Precautions\t\t\t\t\t\t\t<\/h5>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<span class=\"item-divider\" aria-hidden=\"true\"><\/span>\n\t\t\t\t\t\t\t\t\t\t\t<div id=\"the7-e-tab-title-1874\" class=\"the7-e-tab-title\" aria-selected=\"false\" data-tab=\"4\" role=\"tab\" tabindex=\"-1\" aria-controls=\"the7-e-tab-content-1874\" aria-expanded=\"false\">\n\t\t\t\t\t\t\t\t\t\t<span class=\"the7-e-tab-icon elementor-icon\" aria-hidden=\"true\"><i class=\"fas fa-hand-holding-medical\"><\/i><\/span>\n\t\t\t\t\t\t\t\t\t\t<h5 class=\"the7-e-tab-title-text\">\n\t\t\t\t\t\t\tDosage & Administration\t\t\t\t\t\t\t<\/h5>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<span class=\"item-divider\" aria-hidden=\"true\"><\/span>\n\t\t\t\t\t\t\t\t\t\t\t<div id=\"the7-e-tab-title-1875\" class=\"the7-e-tab-title\" aria-selected=\"false\" data-tab=\"5\" role=\"tab\" tabindex=\"-1\" aria-controls=\"the7-e-tab-content-1875\" aria-expanded=\"false\">\n\t\t\t\t\t\t\t\t\t\t<span class=\"the7-e-tab-icon elementor-icon\" aria-hidden=\"true\"><i class=\"far fa-bell\"><\/i><\/span>\n\t\t\t\t\t\t\t\t\t\t<h5 class=\"the7-e-tab-title-text\">\n\t\t\t\t\t\t\tAdverse Reactions\t\t\t\t\t\t\t<\/h5>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<span class=\"item-divider\" aria-hidden=\"true\"><\/span>\n\t\t\t\t\t\t\t\t\t\t\t<div id=\"the7-e-tab-title-1876\" class=\"the7-e-tab-title\" aria-selected=\"false\" data-tab=\"6\" role=\"tab\" tabindex=\"-1\" aria-controls=\"the7-e-tab-content-1876\" aria-expanded=\"false\">\n\t\t\t\t\t\t\t\t\t\t<span class=\"the7-e-tab-icon elementor-icon\" aria-hidden=\"true\"><i class=\"fab fa-confluence\"><\/i><\/span>\n\t\t\t\t\t\t\t\t\t\t<h5 class=\"the7-e-tab-title-text\">\n\t\t\t\t\t\t\tDrug Interactions\t\t\t\t\t\t\t<\/h5>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<span class=\"item-divider\" aria-hidden=\"true\"><\/span>\n\t\t\t\t\t\t\t\t\t\t\t<div id=\"the7-e-tab-title-1877\" class=\"the7-e-tab-title\" aria-selected=\"false\" data-tab=\"7\" role=\"tab\" tabindex=\"-1\" aria-controls=\"the7-e-tab-content-1877\" aria-expanded=\"false\">\n\t\t\t\t\t\t\t\t\t\t<span class=\"the7-e-tab-icon elementor-icon\" aria-hidden=\"true\"><i class=\"fas fa-baby\"><\/i><\/span>\n\t\t\t\t\t\t\t\t\t\t<h5 class=\"the7-e-tab-title-text\">\n\t\t\t\t\t\t\t Pregnancy and Lactation\t\t\t\t\t\t\t<\/h5>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<span class=\"item-divider\" aria-hidden=\"true\"><\/span>\n\t\t\t\t\t\t\t\t\t\t\t<div id=\"the7-e-tab-title-1878\" class=\"the7-e-tab-title\" aria-selected=\"false\" data-tab=\"8\" role=\"tab\" tabindex=\"-1\" aria-controls=\"the7-e-tab-content-1878\" aria-expanded=\"false\">\n\t\t\t\t\t\t\t\t\t\t<span class=\"the7-e-tab-icon elementor-icon\" aria-hidden=\"true\"><i class=\"fas fa-box\"><\/i><\/span>\n\t\t\t\t\t\t\t\t\t\t<h5 class=\"the7-e-tab-title-text\">\n\t\t\t\t\t\t\tStorage Conditions\t\t\t\t\t\t\t<\/h5>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<span class=\"item-divider\" aria-hidden=\"true\"><\/span>\n\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t\t<div class=\"the7-e-tab-nav-button left-button\"><\/div>\n\t\t\t<div class=\"the7-e-tab-nav-button right-button\"><\/div>\n\t\t<\/div>\n\t\t<div class=\"the7-e-tabs-content\" role=\"tablist\" aria-orientation=\"vertical\">\n\t\t\t<span class=\"item-divider\" aria-hidden=\"true\"><\/span>\n\t\t\t\t\t\t\t<div class=\"the7-e-tab-item-wrapper\" data-tab=\"1\">\n\t\t\t\t\t<div class=\"the7-e-tab-title\" aria-selected=\"true\" data-tab=\"1\" role=\"tab\" tabindex=\"0\" aria-controls=\"elementor-tab-content-1871\" aria-expanded=\"false\">\n\t\t\t\t\t\t\t\t\t<span class=\"the7-e-tab-icon elementor-icon\" aria-hidden=\"true\"><i class=\"fas fa-virus\"><\/i><\/span>\n\t\t\t\t\t\t\t\t\t<h5 class=\"the7-e-tab-title-text\">\n\t\t\t\t\t\t\tIndications\t\t\t\t\t\t<\/h5>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t<div id=\"the7-e-tab-content-1871\" class=\"the7-e-tab-content the7-e-tab-text-content\" data-tab=\"1\" role=\"tabpanel\" aria-labelledby=\"the7-e-tab-title-1871\" tabindex=\"0\" hidden=\"false\"><ul><li><strong>Testicular cancer<\/strong><\/li><\/ul><p>Etopodal<sup>\u00ae<\/sup> is indicated in combination with other approved chemotherapeutic agents for the treatment of first line, recurrent or refractory testicular cancer in adults.<\/p><ul><li><strong>Small cell lung cancer<\/strong><\/li><\/ul><p>Etopodal<sup>\u00ae<\/sup> is indicated in combination with other approved chemotherapeutic agents for the treatment of small cell lung cancer in adults.<\/p><ul><li><strong>Hodgkin&#8217;s lymphoma<\/strong><\/li><\/ul><p>Etopodal<sup>\u00ae<\/sup> is indicated in combination with other approved chemotherapeutic agents for the treatment of Hodgkin&#8217;s lymphoma in adult and paediatric patients.<\/p><ul><li><strong>Non-Hodgkin&#8217;s lymphoma<\/strong><\/li><\/ul><p>Etopodal<sup>\u00ae<\/sup> is indicated in combination with other approved chemotherapeutic agents for the treatment of non-Hodgkin&#8217;s lymphoma in adult and paediatric patients.<\/p><ul><li><strong>Acute myeloid leukaemia<\/strong><\/li><\/ul><p>Etopodal<sup>\u00ae<\/sup> is indicated in combination with other approved chemotherapeutic agents for the treatment of acute myeloid leukaemia in adult and paediatric patients.<\/p><ul><li><strong>Gestational trophoblastic neoplasia<\/strong><\/li><\/ul><p>Etopodal<sup>\u00ae<\/sup> is indicated for first line and second line therapy in combination with other approved chemotherapeutic agents for the treatment of high risk gestational trophoblastic neoplasia in adults.<\/p><ul><li><strong>Ovarian cancer<\/strong><\/li><\/ul><p>Etopodal<sup>\u00ae<\/sup> is indicated in combination with other approved chemotherapeutic agents for the treatment of non-epithelial ovarian cancer in adults.<\/p><p>Etopodal<sup>\u00ae<\/sup> is indicated for the treatment of platinum-resistant\/refractory epithelial ovarian cancer in adults.<\/p><\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<span class=\"item-divider\" aria-hidden=\"true\"><\/span>\n\t\t\t\t\t\t\t<div class=\"the7-e-tab-item-wrapper\" data-tab=\"2\">\n\t\t\t\t\t<div class=\"the7-e-tab-title\" aria-selected=\"false\" data-tab=\"2\" role=\"tab\" tabindex=\"-1\" aria-controls=\"elementor-tab-content-1872\" aria-expanded=\"false\">\n\t\t\t\t\t\t\t\t\t<span class=\"the7-e-tab-icon elementor-icon\" aria-hidden=\"true\"><i class=\"fas fa-virus-slash\"><\/i><\/span>\n\t\t\t\t\t\t\t\t\t<h5 class=\"the7-e-tab-title-text\">\n\t\t\t\t\t\t\tContradications\t\t\t\t\t\t<\/h5>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t<div id=\"the7-e-tab-content-1872\" class=\"the7-e-tab-content the7-e-tab-text-content\" data-tab=\"2\" role=\"tabpanel\" aria-labelledby=\"the7-e-tab-title-1872\" tabindex=\"0\" hidden=\"hidden\"><ul><li>Hypersensitivity to the active substance or to any of the excipients such as Citric acid (anhydrous), Polysorbate 80, Macrogol 300 and Ethanol.<\/li><li>Concomitant use of yellow fever vaccine or other live vaccines is contraindicated in immunosuppressed patients.<\/li><li>Lactation.<\/li><\/ul><\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<span class=\"item-divider\" aria-hidden=\"true\"><\/span>\n\t\t\t\t\t\t\t<div class=\"the7-e-tab-item-wrapper\" data-tab=\"3\">\n\t\t\t\t\t<div class=\"the7-e-tab-title\" aria-selected=\"false\" data-tab=\"3\" role=\"tab\" tabindex=\"-1\" aria-controls=\"elementor-tab-content-1873\" aria-expanded=\"false\">\n\t\t\t\t\t\t\t\t\t<span class=\"the7-e-tab-icon elementor-icon\" aria-hidden=\"true\"><i class=\"fas fa-list-ul\"><\/i><\/span>\n\t\t\t\t\t\t\t\t\t<h5 class=\"the7-e-tab-title-text\">\n\t\t\t\t\t\t\tWarnings and Precautions\t\t\t\t\t\t<\/h5>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t<div id=\"the7-e-tab-content-1873\" class=\"the7-e-tab-content the7-e-tab-text-content\" data-tab=\"3\" role=\"tabpanel\" aria-labelledby=\"the7-e-tab-title-1873\" tabindex=\"0\" hidden=\"hidden\"><p>Etopodal<sup>\u00ae<\/sup> should only be administered under the supervision of a qualified physician experienced in the use of anti-neoplastic medicinal products. In all instances where the use of Etopodal<sup>\u00ae<\/sup> is considered for chemotherapy, the physician must evaluate the need and usefulness of the medicinal product against the risk of adverse reactions. Most such adverse reactions are reversible if detected early. If severe reactions occur, the medicinal product should be reduced in dose or discontinued and appropriate corrective measures should be taken according to the clinical judgment of the physician. Reinstitution of Etopodal<sup>\u00ae<\/sup> therapy should be carried out with caution, and with adequate consideration of the further need for the medicinal product and close attention to possible recurrence of toxicity.<\/p><p><u>Myelosuppression<\/u><\/p><p>Dose-limiting bone marrow suppression is the most significant toxicity associated with Etopodal<sup>\u00ae<\/sup> therapy. Fatal myelosuppression has been reported following Etopodal<sup>\u00ae<\/sup> administration. Patients being treated with Etopodal<sup>\u00ae<\/sup> must be observed for myelosuppression carefully and frequently both during and after therapy.<\/p><p>The following haematological parameters should be measured at the start of therapy and prior to each subsequent dose of Etopodal<sup>\u00ae<\/sup>: platelet count, haemoglobin, white blood cell count and differential. If radiotherapy or chemotherapy has been given prior to starting Etopodal<sup>\u00ae<\/sup> treatment, an adequate interval should be allowed to enable the bone marrow to recover. Etopodal<sup>\u00ae<\/sup> should not be administered to patients with neutrophil counts below 1,500 cells\/mm<sup>3<\/sup>\u00a0or platelet counts below 100,000 cells\/mm<sup>3<\/sup>, unless caused by malignant disease.<\/p><p>Doses subsequent to the initial dose should be adjusted if neutrophil count below 500 cells\/mm<sup>3<\/sup>\u00a0occurs for more than 5 days or is associated with fever or infection, if platelet count below 25,000 cells\/mm<sup>3<\/sup>\u00a0occurs, if any other grade 3 or 4 toxicity develops or if renal clearance is less than 50 ml\/min.<\/p><p>Severe myelosuppression with resulting infection or haemorrhage may occur. Bacterial infections should be brought under control before treatment with Etopodal<sup>\u00ae<\/sup>.<\/p><p><u>Secondary leukaemia<\/u><\/p><p>The occurrence of acute leukaemia, which can occur with or without myelodysplastic syndrome, has been described in patients that were treated with etoposide-containing chemotherapeutic regimens.<\/p><p>Neither the cumulative risk, nor the predisposing factors related to the development of secondary leukaemia are known. The roles of both administration schedules and cumulative doses of Etopodal<sup>\u00ae<\/sup> have been suggested, but have not been clearly defined.<\/p><p>An 11q23 chromosome abnormality has been observed in some cases of secondary leukaemia in patients who have received epipodophyllotoxins. This abnormality has also been seen in patients developing secondary leukaemia after being treated with chemotherapy regimens not containing epipodophyllotoxins and in leukaemia occurring\u00a0<em>de novo.<\/em>\u00a0Another characteristic that has been associated with secondary leukaemia in patients who have received epipodophyllotoxins appears to be a short latency period, with average median time to development of leukaemia being approximately 32 months.<\/p><p><u>Hypersensitivity<\/u><\/p><p>Physicians should be aware of the possible occurrence of an anaphylactic reaction with Etopodal<sup>\u00ae<\/sup><strong>,<\/strong>\u00a0manifested by chills, fever, tachycardia, bronchospasm, dyspnoea and hypotension, which can be fatal. Treatment is symptomatic. Etopodal<sup>\u00ae<\/sup> should be terminated immediately, followed by the administration of pressor agents, corticosteroids, antihistamines, or volume expanders at the discretion of the physician.<\/p><p><u>Hypotension<\/u><\/p><p>Etopodal<sup>\u00ae<\/sup> should be given only by slow intravenous infusion (usually over a 30 to 60 minute period) since hypotension has been reported as a possible side effect of rapid intravenous injection.<\/p><p><u>Injection site reaction<\/u><\/p><p>Injection site reactions may occur during the administration of Etopodal<sup>\u00ae<\/sup>. Given the possibility of extravasation, it is recommended to closely monitor the infusion site for possible infiltration during administration of the medicinal product.<\/p><p><u>Low serum albumin<\/u><\/p><p>Low serum albumin is associated with increased exposure to Etopodal<sup>\u00ae<\/sup>. Therefore patients with low serum albumin may be at increased risk for Etopodal<sup>\u00ae<\/sup>-associated toxicities.<\/p><p><u>Impaired renal function<\/u><\/p><p>In patients with moderate (CrCl = 15 to 50 ml\/min), or severe (CrCl &lt; 15 ml\/min) renal impairment undergoing haemodialysis, Etopodal<sup>\u00ae<\/sup> should be administered at a reduced dose. Haematological parameters should be measured and dose adjustments in subsequent cycles considered based on haematological toxicity and clinical effect in patients with moderate and severe renal impairment.<\/p><p><u>Impaired hepatic function<\/u><\/p><p>Patients with impaired hepatic function should regularly have their hepatic function monitored due to the risk of accumulation.<\/p><p><u>Tumour lysis syndrome<\/u><\/p><p>Tumour lysis syndrome (sometimes fatal) has been reported following the use of etoposide in association with other chemotherapeutic medicinal products. Close monitoring of patients is needed to detect early signs of tumour lysis syndrome, especially in patients with risk factors such as bulky treatment-sensitive tumours and renal insufficiency. Appropriate preventive measures should also be considered in patients at risk of this complication of therapy.<\/p><p><u>Mutagenic potential<\/u><\/p><p>Given the mutagenic potential of Etopodal<sup>\u00ae<\/sup>, an effective method of contraception is required for both male and female patients during treatment and up to 6 months after ending treatment. Genetic consultation is recommended if the patient wishes to have children after ending the treatment. As Etopodal<sup>\u00ae<\/sup> may decrease male fertility, preservation of sperm may be considered for the purpose of later fatherhood.<\/p><p><u>Paediatric population<\/u><\/p><p>The clinician should be aware that Etopodal<sup>\u00ae<\/sup> contains ethanol and polysorbate 80 as excipients.<\/p><p><u>Excipients<\/u><\/p><p>This medicinal product contains ethanol (alcohol. Harmful for those suffering from alcoholism. To be taken into account in pregnant or breastfeeding women, children and high-risk groups such as patients with liver disease, or epilepsy.<\/p><p>Consideration should be given to possible effects on the central nervous system.<\/p><p>The amount of alcohol in this medicinal product may alter the effects of other medicinal products.<\/p><p>The amount of alcohol in this medicinal product may impair the patient&#8217;s ability to drive or use machines.<\/p><p>Etoposide injection contains polysorbate 80. In premature infants a life threatening syndrome of liver and renal failure, pulmonary deterioration, thrombocytopenia and ascites has been associated with an injectable vitamin E product containing polysorbate 80.<\/p><\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<span class=\"item-divider\" aria-hidden=\"true\"><\/span>\n\t\t\t\t\t\t\t<div class=\"the7-e-tab-item-wrapper\" data-tab=\"4\">\n\t\t\t\t\t<div class=\"the7-e-tab-title\" aria-selected=\"false\" data-tab=\"4\" role=\"tab\" tabindex=\"-1\" aria-controls=\"elementor-tab-content-1874\" aria-expanded=\"false\">\n\t\t\t\t\t\t\t\t\t<span class=\"the7-e-tab-icon elementor-icon\" aria-hidden=\"true\"><i class=\"fas fa-hand-holding-medical\"><\/i><\/span>\n\t\t\t\t\t\t\t\t\t<h5 class=\"the7-e-tab-title-text\">\n\t\t\t\t\t\t\tDosage & Administration\t\t\t\t\t\t<\/h5>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t<div id=\"the7-e-tab-content-1874\" class=\"the7-e-tab-content the7-e-tab-text-content\" data-tab=\"4\" role=\"tabpanel\" aria-labelledby=\"the7-e-tab-title-1874\" tabindex=\"0\" hidden=\"hidden\"><p>Etopodal<sup>\u00ae<\/sup> must only be administered under the supervision of a physician qualified in the use of anti\u00adcancer chemotherapy.<\/p><ul><li><strong>Dosage:<\/strong><\/li><\/ul><p><em>Adult population<\/em><\/p><p>The recommended dose of Etopodal<sup>\u00ae<\/sup> in adult patients is 50 to 100 mg\/m<sup>2<\/sup>\/day on days 1 to 5 or 100 to 120 mg\/m<sup>2<\/sup>\u00a0on days 1, 3, and 5 every 3 to 4 weeks in combination with other drugs indicated in the disease to be treated. Dosage should be modified to take into account the myelosuppressive effects of other drugs in the combination or the effects of prior radiotherapy or chemotherapy which may have compromised bone marrow reserve. The doses after the initial dose should be adjusted if neutrophil count is below 500 cells\/mm<sup>3<\/sup>\u00a0for more than 5 days. In addition the dose should be adjusted in case of occurrence of fever, infections, or at a thrombocyte count below 25,000 cells\/mm<sup>3<\/sup>, which is not caused by the disease. Follow up doses should be adjusted in case of occurrence of grade 3 or 4 toxicities or if renal creatinine clearance is below 50 ml\/min. At decreased creatinine clearance of 15 to 50 ml\/min a dose reduction by 25% is recommended.<\/p><p>Administration Precautions: As with other potentially toxic compounds, caution should be exercised in handling and preparing the solution of Etopodal<sup>\u00ae<\/sup>. Skin reactions associated with accidental exposure to Etopodal<sup>\u00ae <\/sup>may occur. The use of gloves is recommended. If Etopodal<sup>\u00ae<\/sup> solution contacts the skin or mucosa, immediately wash the skin with soap and water and flush the mucosa with water.<\/p><p><em>Elderly population<\/em><\/p><p>No dosage adjustment is necessary in elderly patients (age &gt; 65 years old), other than based on renal function.<\/p><p><em>Paediatric population<\/em><\/p><p><u>Hodgkin&#8217;s lymphoma; non-Hodgkin&#8217;s lymphoma; acute myeloid leukaemia<\/u><\/p><p>Etopodal<sup>\u00ae<\/sup> in paediatric patients has been used in the range of 75 to 150 mg\/m<sup>2<\/sup>\/day for 2 to 5 days in combination with other antineoplastic agents. The treatment regimen should be chosen according to the local standard of care.<\/p><p><u>Ovarian cancer; small cell lung cancer; gestational trophoblastic neoplasia; testicular cancer<\/u><\/p><p>The safety and efficacy of etoposide below 18 years of age have not been established.<\/p><p><em>Renal impairment<\/em><\/p><p>In patients with impaired renal function, the following initial dose modification should be considered based on measured creatinine clearance.<\/p><table width=\"691\"><tbody><tr><td width=\"45%\"><p>Measured creatinine clearance<\/p><\/td><td width=\"55%\"><p>Dose of Etopodal<sup>\u00ae<\/sup><\/p><\/td><\/tr><tr><td width=\"45%\"><p>&gt; 50 ml\/min<\/p><\/td><td width=\"55%\"><p>100 % of dose<\/p><\/td><\/tr><tr><td width=\"45%\"><p>15 &#8211; 50 ml\/min<\/p><\/td><td width=\"55%\"><p>75 % of dose<\/p><\/td><\/tr><\/tbody><\/table><p>In patients with creatinine clearance less than 15 ml\/min and on dialysis further dose\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 reduction is likely to be required as Etopodal<sup>\u00ae<\/sup> clearance is further reduced in these patients. Subsequent dosing in moderate and severe renal impairment should be based on patient tolerance and clinical effect. Since Etopodal<sup>\u00ae<\/sup> and its metabolites are not \u00a0\u00a0dialyzable, it can be administered pre- and post-haemodialysis.<\/p><ul><li><strong>Preparation and administration<\/strong><\/li><\/ul><p>Etopodal<sup>\u00ae<\/sup> should only be administered and monitored under the supervision of a qualified physician experienced in the use of anti-neoplastic medicinal products.<\/p><p>Etopodal<sup>\u00ae<\/sup> \u00a0is administered by slow intravenous infusion (usually over a 30 to 60 minute period).<\/p><p>Concentrate for solution for infusion must not be used undiluted.<\/p><p>Etopodal<sup>\u00ae<\/sup> should not be mixed with other medicinal products.<\/p><p>Etopodal<sup>\u00ae<\/sup> should be stored out of the sight and reach of children.<\/p><p>Etopodal<sup>\u00ae<\/sup> should only be diluted with sodium chloride 9 mg\/ml (0.9 %) solution for injection or 5 % glucose solution. The concentration of Etopodal<sup>\u00ae<\/sup> \u00a0in the reconstituted solution for infusion should not exceed 0.4 mg\/ml due to the risk of precipitation.<\/p><\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<span class=\"item-divider\" aria-hidden=\"true\"><\/span>\n\t\t\t\t\t\t\t<div class=\"the7-e-tab-item-wrapper\" data-tab=\"5\">\n\t\t\t\t\t<div class=\"the7-e-tab-title\" aria-selected=\"false\" data-tab=\"5\" role=\"tab\" tabindex=\"-1\" aria-controls=\"elementor-tab-content-1875\" aria-expanded=\"false\">\n\t\t\t\t\t\t\t\t\t<span class=\"the7-e-tab-icon elementor-icon\" aria-hidden=\"true\"><i class=\"far fa-bell\"><\/i><\/span>\n\t\t\t\t\t\t\t\t\t<h5 class=\"the7-e-tab-title-text\">\n\t\t\t\t\t\t\tAdverse Reactions\t\t\t\t\t\t<\/h5>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t<div id=\"the7-e-tab-content-1875\" class=\"the7-e-tab-content the7-e-tab-text-content\" data-tab=\"5\" role=\"tabpanel\" aria-labelledby=\"the7-e-tab-title-1875\" tabindex=\"0\" hidden=\"hidden\"><ul><li><strong>&gt;10%:<\/strong><\/li><\/ul><p>Dermatologic: Alopecia (8% to 66%)<\/p><p>Gastrointestinal: Nausea and vomiting (31% to 43%), anorexia (10% to 13%), diarrhea (1% to 13%)<\/p><p>Hematologic &amp; oncologic: Leukopenia (60% to 91%; grade 4: 3% to 17%; nadir: 7 to 14 days; recovery: by day 20), thrombocytopenia (22% to 41%; grades 3\/4: 1% to 20%; nadir: 9 to 16 days; recovery: by day 20), anemia (\u226433%)<\/p><ul><li><strong>1% to 10%:<\/strong><\/li><\/ul><p>Cardiovascular: Hypotension (1% to 2%; due to rapid infusion)<\/p><p>Central nervous system: Peripheral neuropathy (1% to 2%)<\/p><p>Gastrointestinal: Stomatitis (1% to 6%), abdominal pain (\u22642%)<\/p><p>Hepatic: Hepatotoxicity (\u22643%)<\/p><p>Hypersensitivity: Anaphylactoid reaction (intravenous: 1% to 2%; oral capsules: &lt;1%; including bronchospasm, chills, dyspnea, fever, tachycardia)<\/p><ul><li><strong>&lt;1%<\/strong><\/li><\/ul><p>postmarketing, and\/or case reports: Amenorrhea, apnea (hypersensitivity-associated), back pain, constipation, cortical blindness (transient), cough, cyanosis, diaphoresis, drowsiness, dysphagia, erythema, esophagitis, extravasation (induration\/necrosis), facial swelling, fatigue, fever, hyperpigmentation, hypersensitivity reaction, interstitial pneumonitis, ischemic heart disease, laryngospasm, maculopapular rash, malaise, metabolic acidosis, mucositis, myocardial infarction, optic neuritis, ovarian failure, pruritic erythematous rash, pruritus, pulmonary fibrosis, radiation-recall phenomenon (dermatitis), reversible posterior leukoencephalopathy syndrome (RPLS), seizure, skin rash, Stevens-Johnson syndrome, tongue edema, toxic epidermal necrolysis, toxic megacolon, urticaria, vasospasm, weakness<\/p><p><strong><em><u>Reporting of suspected adverse reactions<\/u><\/em><\/strong><\/p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit\/risk balance of the medicinal product. Please report any adverse drug reactions via contacting Cedal Nano.<\/p><\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<span class=\"item-divider\" aria-hidden=\"true\"><\/span>\n\t\t\t\t\t\t\t<div class=\"the7-e-tab-item-wrapper\" data-tab=\"6\">\n\t\t\t\t\t<div class=\"the7-e-tab-title\" aria-selected=\"false\" data-tab=\"6\" role=\"tab\" tabindex=\"-1\" aria-controls=\"elementor-tab-content-1876\" aria-expanded=\"false\">\n\t\t\t\t\t\t\t\t\t<span class=\"the7-e-tab-icon elementor-icon\" aria-hidden=\"true\"><i class=\"fab fa-confluence\"><\/i><\/span>\n\t\t\t\t\t\t\t\t\t<h5 class=\"the7-e-tab-title-text\">\n\t\t\t\t\t\t\tDrug Interactions\t\t\t\t\t\t<\/h5>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t<div id=\"the7-e-tab-content-1876\" class=\"the7-e-tab-content the7-e-tab-text-content\" data-tab=\"6\" role=\"tabpanel\" aria-labelledby=\"the7-e-tab-title-1876\" tabindex=\"0\" hidden=\"hidden\"><p><u>Effects of other medicinal products on the pharmacokinetics of <\/u><u>Etopodal<sup>\u00ae<\/sup><\/u><\/p><p>High-dose cyclosporine, resulting in concentrations above 2000 ng\/ml, administered with oral etoposide has led to an 80 % increase in etoposide exposure (AUC) with a 38 % decrease in total body clearance of etoposide compared to etoposide alone.<\/p><p>Concomitant cisplatin therapy is associated with reduced etoposide clearance.<\/p><p>Concomitant phenytoin therapy is associated with increased etoposide clearance and reduced efficacy, and other enzyme-inducing antiepileptic therapy may be associated with increased etoposide clearance and reduced efficacy.<\/p><p><em>In vitro<\/em>\u00a0plasma protein binding is 97 %. Phenylbutazone, sodium salicylate and acetylsalicylic acid may displace etoposide from plasma protein binding.<\/p><p><u>Effect of <\/u><u>Etopodal<sup>\u00ae<\/sup><\/u><u> on the pharmacokinetics of other medicinal products<\/u><\/p><p>Co-administration of antiepileptic medicinal products and etoposide can lead to decreased seizure control due to pharmacokinetic interactions between the medicinal products.<\/p><p>Co-administration of warfarin and etoposide may result in elevated international normalized ratio (INR). Close monitoring of INR is recommended.<\/p><p><u>Pharmacodynamic interactions<\/u><\/p><p>There is increased risk of fatal systemic vaccinal disease with the use of yellow fever vaccine.<strong>\u00a0<\/strong>Live vaccines are contraindicated in immunosuppressed patients.<\/p><p>Prior or concurrent use of other medicinal products with similar myelosuppressant action as Etopodal<sup>\u00ae<\/sup> may be expected to have additive or synergetic effects.<\/p><p>Cross-resistance between anthracyclines and etoposide has been reported in preclinical experiments.<\/p><p><u>Paediatric population<\/u><\/p><p>Interaction studies have only been performed in adults.<\/p><\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<span class=\"item-divider\" aria-hidden=\"true\"><\/span>\n\t\t\t\t\t\t\t<div class=\"the7-e-tab-item-wrapper\" data-tab=\"7\">\n\t\t\t\t\t<div class=\"the7-e-tab-title\" aria-selected=\"false\" data-tab=\"7\" role=\"tab\" tabindex=\"-1\" aria-controls=\"elementor-tab-content-1877\" aria-expanded=\"false\">\n\t\t\t\t\t\t\t\t\t<span class=\"the7-e-tab-icon elementor-icon\" aria-hidden=\"true\"><i class=\"fas fa-baby\"><\/i><\/span>\n\t\t\t\t\t\t\t\t\t<h5 class=\"the7-e-tab-title-text\">\n\t\t\t\t\t\t\t Pregnancy and Lactation\t\t\t\t\t\t<\/h5>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t<div id=\"the7-e-tab-content-1877\" class=\"the7-e-tab-content the7-e-tab-text-content\" data-tab=\"7\" role=\"tabpanel\" aria-labelledby=\"the7-e-tab-title-1877\" tabindex=\"0\" hidden=\"hidden\"><ul><li><strong>Pregnancy<\/strong><\/li><\/ul><p>There are no or limited amount of data from the use of etoposide in pregnant women. Studies in animals have shown reproductive toxicity. In general etoposide can cause foetal harm when administered to pregnant women. Etopodal<sup>\u00ae<\/sup> should not be used during pregnancy unless the clinical condition of the woman requires treatment with Etopodal<sup>\u00ae<\/sup>.<\/p><p>Women of childbearing potential should be advised to avoid becoming pregnant. Women of childbearing potential have to use effective contraception during and up to 6 months after treatment. If this medicinal product is used during pregnancy, or if the patient becomes pregnant while receiving this medicinal product, the patient should be informed of the potential hazard to the fetus.<\/p><ul><li><strong>Breastfeeding<\/strong><\/li><\/ul><p>Etopodal<sup>\u00ae<\/sup> is excreted in human milk. There is the potential for serious adverse reactions in nursing infants from Etopodal<sup>\u00ae<\/sup>. Therefore, Etopodal<sup>\u00ae<\/sup> is contraindicated during breast-feeding. A decision must be made whether to discontinue breast-feeding or to discontinue Etopodal<sup>\u00ae<\/sup> taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.<\/p><\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<span class=\"item-divider\" aria-hidden=\"true\"><\/span>\n\t\t\t\t\t\t\t<div class=\"the7-e-tab-item-wrapper\" data-tab=\"8\">\n\t\t\t\t\t<div class=\"the7-e-tab-title\" aria-selected=\"false\" data-tab=\"8\" role=\"tab\" tabindex=\"-1\" aria-controls=\"elementor-tab-content-1878\" aria-expanded=\"false\">\n\t\t\t\t\t\t\t\t\t<span class=\"the7-e-tab-icon elementor-icon\" aria-hidden=\"true\"><i class=\"fas fa-box\"><\/i><\/span>\n\t\t\t\t\t\t\t\t\t<h5 class=\"the7-e-tab-title-text\">\n\t\t\t\t\t\t\tStorage Conditions\t\t\t\t\t\t<\/h5>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t<div id=\"the7-e-tab-content-1878\" class=\"the7-e-tab-content the7-e-tab-text-content\" data-tab=\"8\" role=\"tabpanel\" aria-labelledby=\"the7-e-tab-title-1878\" tabindex=\"0\" hidden=\"hidden\"><ul><li><strong>Shelf life<\/strong><\/li><\/ul><p>Unopened vial: 2 years.<\/p><p>Once opened, the product is chemically and microbiologically stable for five days.<\/p><p>The physical and chemical in-use stability of the diluted product (0.2 mg\/ml and 0.4 mg\/ml) has been demonstrated for 24 hours at 20 \u00b0C to 25 \u00b0C.<\/p><p>From a microbiological point of view, unless the method of dilution precludes the risk of microbial contamination, the diluted product should be used immediately.<\/p><p>If not used immediately, in-use storage times and conditions are the responsibility of the user.<\/p><p>When the diluted product is stored in PVC bags a leaching of plasticizer in the product or precipitation<\/p><ul><li><strong>Special precautions for storage<\/strong><\/li><\/ul><p>Do not refrigerate or freeze.<\/p><\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<span class=\"item-divider\" aria-hidden=\"true\"><\/span>\n\t\t\t\t\t<\/div>\n\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<section class=\"elementor-section elementor-inner-section elementor-element elementor-element-bfb49cc elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"bfb49cc\" data-element_type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-inner-column elementor-element elementor-element-ef0757c\" data-id=\"ef0757c\" data-element_type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-7458884 icon-box-vertical-align-center elementor-widget__width-auto elementor-hidden-desktop elementor-hidden-tablet elementor-hidden-mobile content-align-left icon-position-left icon-vertical-align-start elementor-widget elementor-widget-the7_icon_box_widget\" data-id=\"7458884\" data-element_type=\"widget\" data-widget_type=\"the7_icon_box_widget.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\n\t\t<div class=\"the7-box-wrapper the7-elementor-widget the7_icon_box_widget-7458884\">\t\t\t<div class=\"box-content-wrapper\">\n\t\t\t\t\t\t\t\t<div class=\"box-content\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h4 class=\"box-heading\">\n\t\t\t\t\t\t\t<a href=\"\/wp-content\/uploads\/2023\/02\/5FUEnglish.docx\">\t\t\t\t\t\t\t\tProduct Description File\t\t\t\t\t\t\t<\/a>\t\t\t\t\t\t<\/h4>\n\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-f762e58 elementor-share-buttons--view-icon elementor-share-buttons--skin-minimal elementor-share-buttons--shape-circle elementor-grid-mobile-6 elementor-share-buttons--align-left elementor-share-buttons--color-custom elementor-widget__width-auto elementor-grid-0 elementor-widget elementor-widget-share-buttons\" data-id=\"f762e58\" data-element_type=\"widget\" data-widget_type=\"share-buttons.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<div class=\"elementor-grid\">\n\t\t\t\t\t\t\t\t<div class=\"elementor-grid-item\">\n\t\t\t\t\t\t<div\n\t\t\t\t\t\t\tclass=\"elementor-share-btn elementor-share-btn_twitter\"\n\t\t\t\t\t\t\trole=\"button\"\n\t\t\t\t\t\t\ttabindex=\"0\"\n\t\t\t\t\t\t\taria-label=\"Share on twitter\"\n\t\t\t\t\t\t>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-share-btn__icon\">\n\t\t\t\t\t\t\t\t<i class=\"fab fa-twitter\" aria-hidden=\"true\"><\/i>\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-grid-item\">\n\t\t\t\t\t\t<div\n\t\t\t\t\t\t\tclass=\"elementor-share-btn elementor-share-btn_linkedin\"\n\t\t\t\t\t\t\trole=\"button\"\n\t\t\t\t\t\t\ttabindex=\"0\"\n\t\t\t\t\t\t\taria-label=\"Share on linkedin\"\n\t\t\t\t\t\t>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-share-btn__icon\">\n\t\t\t\t\t\t\t\t<i class=\"fab fa-linkedin\" aria-hidden=\"true\"><\/i>\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-grid-item\">\n\t\t\t\t\t\t<div\n\t\t\t\t\t\t\tclass=\"elementor-share-btn elementor-share-btn_whatsapp\"\n\t\t\t\t\t\t\trole=\"button\"\n\t\t\t\t\t\t\ttabindex=\"0\"\n\t\t\t\t\t\t\taria-label=\"Share on whatsapp\"\n\t\t\t\t\t\t>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-share-btn__icon\">\n\t\t\t\t\t\t\t\t<i class=\"fab fa-whatsapp\" aria-hidden=\"true\"><\/i>\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-grid-item\">\n\t\t\t\t\t\t<div\n\t\t\t\t\t\t\tclass=\"elementor-share-btn elementor-share-btn_telegram\"\n\t\t\t\t\t\t\trole=\"button\"\n\t\t\t\t\t\t\ttabindex=\"0\"\n\t\t\t\t\t\t\taria-label=\"Share on telegram\"\n\t\t\t\t\t\t>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-share-btn__icon\">\n\t\t\t\t\t\t\t\t<i class=\"fab fa-telegram\" aria-hidden=\"true\"><\/i>\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-grid-item\">\n\t\t\t\t\t\t<div\n\t\t\t\t\t\t\tclass=\"elementor-share-btn elementor-share-btn_print\"\n\t\t\t\t\t\t\trole=\"button\"\n\t\t\t\t\t\t\ttabindex=\"0\"\n\t\t\t\t\t\t\taria-label=\"Share on print\"\n\t\t\t\t\t\t>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-share-btn__icon\">\n\t\t\t\t\t\t\t\t<i class=\"fas fa-print\" aria-hidden=\"true\"><\/i>\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>Generic Name Etoposide Brand Name \u00aeEtopodal Drug Class Antineoplastic Agent, Topoisomerase II Inhibitor Dosage Form Solution for infusion 20mg\/ml (100 &#038; 200ml) Indications Contradications Warnings and Precautions Dosage &#038; Administration Adverse Reactions Drug Interactions Pregnancy and Lactation Storage Conditions Indications Testicular cancer Etopodal\u00ae is indicated in combination with other approved chemotherapeutic agents for the treatment&hellip;<\/p>\n","protected":false},"author":1,"featured_media":8038,"comment_status":"closed","ping_status":"closed","template":"","dt_portfolio_category":[48],"dt_portfolio_tags":[54,108,110,111,112],"class_list":["post-7502","dt_portfolio","type-dt_portfolio","status-publish","has-post-thumbnail","hentry","dt_portfolio_category-oncology-en","dt_portfolio_tags-cedal-co","dt_portfolio_tags-drug","dt_portfolio_tags-etopodal","dt_portfolio_tags-etoposide","dt_portfolio_tags-injection"],"_links":{"self":[{"href":"https:\/\/cedalco.com\/en\/wp-json\/wp\/v2\/dt_portfolio\/7502","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cedalco.com\/en\/wp-json\/wp\/v2\/dt_portfolio"}],"about":[{"href":"https:\/\/cedalco.com\/en\/wp-json\/wp\/v2\/types\/dt_portfolio"}],"author":[{"embeddable":true,"href":"https:\/\/cedalco.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/cedalco.com\/en\/wp-json\/wp\/v2\/comments?post=7502"}],"version-history":[{"count":32,"href":"https:\/\/cedalco.com\/en\/wp-json\/wp\/v2\/dt_portfolio\/7502\/revisions"}],"predecessor-version":[{"id":12355,"href":"https:\/\/cedalco.com\/en\/wp-json\/wp\/v2\/dt_portfolio\/7502\/revisions\/12355"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cedalco.com\/en\/wp-json\/wp\/v2\/media\/8038"}],"wp:attachment":[{"href":"https:\/\/cedalco.com\/en\/wp-json\/wp\/v2\/media?parent=7502"}],"wp:term":[{"taxonomy":"dt_portfolio_category","embeddable":true,"href":"https:\/\/cedalco.com\/en\/wp-json\/wp\/v2\/dt_portfolio_category?post=7502"},{"taxonomy":"dt_portfolio_tags","embeddable":true,"href":"https:\/\/cedalco.com\/en\/wp-json\/wp\/v2\/dt_portfolio_tags?post=7502"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}